bullish

SciClone Pharma (6600 HK): Scheme Vote on 19 June

752 Views24 May 2024 18:33
This is a done deal. At the last close and for the 12 July payment, the gross and annualised spread is 2.2% and 17.3%, respectively.
What is covered in the Full Insight:
  • Scheme Vote
  • Deal Status
  • Shareholder Standings
  • IFA Evaluation
  • Offer Price Evaluation
Boomeranged on Wed, 29 May 2024 21:57
SciClone has received a letter of support from Pentwater Capital Management to vote YES. Pentwater represents 4.64% of out. shares and 8.51% of disinterested shares, close to the 10% blocking stake of 5.45% of the out. shares. This is a done deal. At the last close and for the 12 July payment, the gross and annualised spread is 2.6% and 23.7%, respectively.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Information TechnologyEquitiesEquity Capital MarketsEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
x